Retrotrope is striving to change aging as we know it, so that people do not have to suffer the ravages of many degenerative diseases. Retrotope is a clinical stage pharmaceutical startup that is leading the advance of a revolutionary new unified theory of aging and degeneration that can result in dramatically new approaches to therapy. It is creating a new category of drugs composed of proprietary compounds that target degenerative diseases, such as Parkinson's, Alzheimer's, mitochondrial myopathies and retinopathies.

Retrotope is currently assessing technical proof of principle, regulatory requirements, and viability of several products in multiple market segments.

Retrotope announces the opening of enrollment for a 28-day, first-in-human, randomized, double-blind, controlled, ascending dose study of orally dosed RT001 to evaluate the safety, tolerability, pharmacokinetics (PK), disease state, and exploratory endpoints in patients with Friedreich’s ataxia (FRDA).

Interview of CEO Dr. Bob Molinari by Kyle Bryant (FARA) about the RT001 First in Human clinical trial in Friedreich's ataxia.

(August 22, 2015)